Sanofi and Regeneron's Dupixent Meets All Endpoints in P-III Study in Children with Atopic Dermatitis
Shots:
- The P-II/III LIBERTY AD PRESCHOOL (part B) involves assessing the efficacy & safety of Dupixent (200/300mg) + low-potency TCS vs TCS alone in 162 children aged 6mos. to 5 years with uncontrolled mod. to sev. AD
- Result: clear or almost-clear skin (28% vs 4%); 75% or greater overall disease improvement (53% vs 11%); improvement in EASI & itch (70% & 49% vs 20% & 2%); 50% reduction in skin infection (12% vs 24%); 70% reduction in total number of infections; improvement in health related QoL measures @16wks.
- The results reinforce the well-established safety profile of Dupixent as the first ever biologic medicine for AD currently approved for patients as young 6yrs. old
| Ref: Globe Newswire | Image: France 24
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com